Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1987 1
1988 1
1990 1
1991 1
1993 1
1994 2
1995 3
1996 4
1997 7
1998 4
1999 7
2000 12
2001 9
2002 16
2003 19
2004 15
2005 19
2006 26
2007 29
2008 33
2009 42
2010 34
2011 45
2012 67
2013 70
2014 75
2015 71
2016 94
2017 111
2018 118
2019 151
2020 197
2021 204
2022 242
2023 233
2024 88

Text availability

Article attribute

Article type

Publication date

Search Results

1,824 results

Results by year

Filters applied: . Clear all
Page 1
Retraction Statement.
[No authors listed] [No authors listed] Int J Clin Pract. 2021 Dec;75(12):e14927. doi: 10.1111/ijcp.14927. Epub 2021 Oct 12. Int J Clin Pract. 2021. PMID: 34636466
Retraction Statement: Ali, M, Imran, M M, Ahmad, U, Usman, U, Shaukat, A, Gul, N Neutrophil/lymphocyte ratio-A marker of COVID-19 pneumonia severity. ...Chinese. 10.12122/j.issn.1673-4254.2020.06.02. PMID: 32895195; PMCID: PMC7321274. Xia X, Wen M, …
Retraction Statement: Ali, M, Imran, M M, Ahmad, U, Usman, U, Shaukat, A, Gul, N Neutrophil/lymphocyte ratio-A marker o …
Retraction Statement.
[No authors listed] [No authors listed] Int J Clin Pract. 2021 Dec;75(12):e14926. doi: 10.1111/ijcp.14926. Epub 2021 Oct 12. Int J Clin Pract. 2021. PMID: 34636459 Free PMC article.
Retraction Statement: Ali, M, Imran, M M, Ahmad, U, Usman, U, Shaukat, A, Gul, N Clinical characteristics and outcomes of patients with COVID-19 pneumonia admitted to an intensive care unit in Faisalabad, Pakistan. ...Chinese. 10.12122/j.issn.1673-4254.2020.0 …
Retraction Statement: Ali, M, Imran, M M, Ahmad, U, Usman, U, Shaukat, A, Gul, N Clinical characteristics and outcomes …
Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors.
Song L, Gao S, Ye B, Yang M, Cheng Y, Kang D, Yi F, Sun JP, Menéndez-Arias L, Neyts J, Liu X, Zhan P. Song L, et al. Acta Pharm Sin B. 2024 Jan;14(1):87-109. doi: 10.1016/j.apsb.2023.08.004. Epub 2023 Aug 9. Acta Pharm Sin B. 2024. PMID: 38239241 Free PMC article. Review.
Numerous non-covalent M(pro) inhibitors with desirable properties have been developed based on available crystal structures of M(pro). ...Prospective viewpoints and insights into current strategies for the development of non-covalent M(pro) inhibitors are als …
Numerous non-covalent M(pro) inhibitors with desirable properties have been developed based on available crystal structures of M
Molecular features, biological behaviors and clinical implications of m(5)C RNA methylation modification regulators in gastrointestinal cancers.
Zhan M, Song H, Tian D, Wen Q, Shi X, Wang Y, Mao X, Wang J. Zhan M, et al. Cancer Biol Ther. 2023 Dec 31;24(1):2223382. doi: 10.1080/15384047.2023.2223382. Cancer Biol Ther. 2023. PMID: 37332118 Free PMC article.
Epitranscriptome studies have shown that critical RNA modifications drive tumorigenicity; however, the role of 5-methylcytosine (m(5)C) RNA methylation remains poorly understood. We extracted 17 m(5)C regulators and clustered distinct m(5)C modification patte …
Epitranscriptome studies have shown that critical RNA modifications drive tumorigenicity; however, the role of 5-methylcytosine (m(5) …
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
Gai D, Chen JR, Stewart JP, Nookaew I, Habelhah H, Ashby C, Sun F, Cheng Y, Li C, Xu H, Peng B, Garg TK, Schinke C, Thanendrarajan S, Zangari M, Chen F, Barlogie B, van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F. Gai D, et al. J Clin Invest. 2022 Sep 15;132(18):e159527. doi: 10.1172/JCI159527. J Clin Invest. 2022. PMID: 35881476 Free PMC article.
We combined PET-CT and gene expression profiling (GEP) of purified BM CD138+ MM cells from 512 newly diagnosed MM patients to reveal that elevated expression of cystatin M/E (CST6) was significantly associated with the absence of OL in MM. ...
We combined PET-CT and gene expression profiling (GEP) of purified BM CD138+ MM cells from 512 newly diagnosed MM patients to reveal that el …
Roles of N(6)-methyladenosine (m(6)A) modifications in gynecologic cancers: mechanisms and therapeutic targeting.
Chen J, Guo B, Liu X, Zhang J, Zhang J, Fang Y, Zhu S, Wei B, Cao Y, Zhan L. Chen J, et al. Exp Hematol Oncol. 2022 Nov 12;11(1):98. doi: 10.1186/s40164-022-00357-z. Exp Hematol Oncol. 2022. PMID: 36371254 Free PMC article. Review.
The m(6)A-related regulatory factors can also be used as therapeutic targets and biomarkers for the early diagnosis of cancers, including gynecologic cancers. This review discusses the role of m(6)A in gynecologic cancers and summarizes the recent advancements in …
The m(6)A-related regulatory factors can also be used as therapeutic targets and biomarkers for the early diagnosis of cancers, inclu …
Disease resistance through M genes.
Zhan C, Wang M. Zhan C, et al. Nat Plants. 2024 Mar;10(3):352-353. doi: 10.1038/s41477-024-01644-9. Nat Plants. 2024. PMID: 38409293 No abstract available.
RNA modifications in cardiovascular diseases, the potential therapeutic targets.
Wu Y, Zhan S, Xu Y, Gao X. Wu Y, et al. Life Sci. 2021 Aug 1;278:119565. doi: 10.1016/j.lfs.2021.119565. Epub 2021 May 6. Life Sci. 2021. PMID: 33965380 Review.
In cardiovascular diseases, a wide range of RNA modifications including m(6)A (N6-adenosine methylation), m(5)C (5-methylcytidin), Nm (2'-O-ribose-methylation), psi (pseudouridine), m(7)G (N7-methylguanosine), and m(1)A (N1-adenosine methylation) have …
In cardiovascular diseases, a wide range of RNA modifications including m(6)A (N6-adenosine methylation), m(5)C (5-methylcytid …
1.7 m figure-9 Tm-doped ultrafast fiber laser.
Lin ZW, Chen JX, Li TJ, Zhan ZY, Liu M, Li C, Luo AP, Zhou P, Xu WC, Luo ZC. Lin ZW, et al. Opt Express. 2022 Aug 29;30(18):32347-32354. doi: 10.1364/OE.468769. Opt Express. 2022. PMID: 36242298 Free article.
The cavity dispersion is compensated to be slightly positive, enabling the proposed 1.7 m ultrafast fiber laser to deliver the dissipative soliton with a 3-dB bandwidth of 20 nm. ...The demonstration of figure-9 Tm-doped ultrafast fiber laser would pave the way to develop …
The cavity dispersion is compensated to be slightly positive, enabling the proposed 1.7 m ultrafast fiber laser to deliver the dissip …
Interplay between Liposomes and IgM: Principles, Challenges, and Opportunities.
Wang H, Lin S, Wu X, Jiang K, Lu H, Zhan C. Wang H, et al. Adv Sci (Weinh). 2023 Jul;10(20):e2301777. doi: 10.1002/advs.202301777. Epub 2023 May 7. Adv Sci (Weinh). 2023. PMID: 37150860 Free PMC article. Review.
However, the application of liposomes encounters major challenges due to the knowledge gaps in their in vivo delivery process. Immunoglobulin M (IgM) displays both pervasiveness and complexity in regulating the biological functions as well as eliciting adverse effects of l …
However, the application of liposomes encounters major challenges due to the knowledge gaps in their in vivo delivery process. Immunoglobuli …
1,824 results